Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Scientists say drugs like Ozempic and Wegovy 'could slash risk of 42 health conditions'
Researchers took drugs currently used to treat type 2 diabetes and obesity and looked into how they affect 175 conditions. They found people taking the jabs were less likely to develop health problems like psychotic disorders, heart disease and dementia.
GLP-1 drugs like Ozempic and Wegovy lower the risk of 42 conditions
The benefits of taking GLP-1 agonists seem to outweigh the risks, at least when taken for approved uses, according to an assessment of how the drugs affect 175 conditions
Ozempic: Landmark study unveils risk and benefits of popular obesity drug
Debate over the risks and benefits of the population weight loss drugs like Ozempic, Wegovy, and Zepbound finally came to an end after a new landmark study.According to Global News, a new observational study published in the journal
Landmark Study Reveals New Benefits and Risks of Obesity Drugs Like Ozempic
A study by the Department of Veterans Affairs says that drugs like Ozempic can do plenty more than just help with weight loss.
Obesity drugs: huge study highlights new health risks
Weight-loss medicines such as Ozempic might raise a person’s likelihood of developing conditions including arthritis.
Ozempic-style drugs tied to more than 60 health benefits and risks in biggest study-of-its-kind
A large new study has shed light on the wider health impacts of taking Ozempic-style drugs. Weight-loss drugs like Ozempic may decrease your risk of developing 42 health conditions, but increase your chance of experiencing 19 others, according to one of the most comprehensive studies-of-its-kind to date.
Largest-ever Ozempic and GLP-1 drug study finds they lower risk of 42 health conditions, including heart attacks and Alzheimer’s disease
The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 receptor agonists.
The Health Risks and Benefits of Weight-Loss Drugs
The newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ways they affect the body—both helpful and harmful—beyond reducing weight. In report published in Nature Medicine,
Ozempic can lower chances of multiple health conditions but comes with risks, study finds
Ozempic, Wegovy, Zepbound and other drugs often used for weight loss can help lower the risk of a wide range of health conditions, according to a new study. But the drugs also pose certain risks. Kyle Benning explains.
1d
on MSN
Will Medicare End Ozempic Maker Novo Nordisk's Obesity Drug Boom?
Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...
4d
Meet ‘Super’ Ozempic: Higher Dose Semaglutide Leads to Even Greater Weight Loss In Major Trial
People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.
7h
on MSN
See ya, knock-off Ozempic
Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...
5d
on MSN
Anti-obesity medication: these are the surprising effects of taking Ozempic and Mounjaro
Anti-obesity medication: these are the surprising effects of taking Ozempic and Mounjaro - When Henry Conway hit his forties ...
17h
on MSN
The Ozempic debate: Large study reveals the good and the bad
A new study shows that GLP-1 drugs offer health benefits such as reducing risks for heart disease but also carry potential ...
2d
on MSN
Ozempic May Damage Vital Organs, Study Finds
An observational study has uncovered a possible link between taking GLP-1s and increased risk of kidney, pancreas and gut ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback